Preface

Resveratrol is a plant-derived stilbene polyphenol marketed as a putative caloric-restriction mimetic and sirtuin (SIRT1) activator. The best current human evidence supports modest, surrogate-level cardiometabolic effects; small reductions in blood pressure and total cholesterol in specific dysmetabolic populations, but there is no high-quality human evidence that resveratrol reduces mortality, prevents age-related disease, or slows biological ageing.[1][2][3] All longevity use is off-label, based on supplements (not licensed medicines), and should be framed to patients as adjunctive and unproven for hard outcomes.


1. Scope

– Covered: Oral resveratrol/trans-resveratrol supplementation in adults for longevity and preventive purposes in a private UK longevity clinic, adjunctive to conventional primary/secondary care.

– Not covered: Red wine/dietary resveratrol as a lifestyle recommendation; intravenous or topical formulations; resveratrol as oncological therapy; combination “sirtuin-activator stacks” (e.g. with NMN/NR) — cross-interactions are not established.

– Framing: Resveratrol is a food supplement in the UK, not an MHRA-licensed medicine. There is no approved indication for ageing. All content below is off-label/expert-consensus unless stated otherwise.



2. Background and pathophysiology

– Biological rationale: Resveratrol is proposed to mimic caloric restriction by activating SIRT1 (an NAD⁺-dependent deacetylase) and downstream PGC-1α, promoting mitochondrial biogenesis, and by activating AMPK, Nrf2 (antioxidant defence) and inhibiting NF-κB (inflammation).[4][5][6]

– Ageing hallmarks targeted (mechanistically): mitochondrial dysfunction, chronic inflammation (“inflammaging”), oxidative stress, and epigenetic/senescence pathways.[7][8]

The following schematic summarises the principal proposed anti-ageing pathways:

Figure 2 The mechanisms of resveratrol against aging. Resveratrol could stimulate the activity of nuclear factor erythroid‐2 related factor 2 (Nrf2) and promote the activities of antioxidant enzymes, like superoxide dismutase (SOD) and catalase (CAT) to inhibit the production of reactive oxygen species (ROS), thus suppressing oxidative stress. Resveratrol could activate antiaging factor sirtuin1 (Sirt1) and downregulate the Akt/mTOR pathway to inhibit ROS in mitochondria and increase mitochondrial biogenesis and function, which could improve mitochondrial function. Resveratrol could promote the activities of nuclear‐factor kappa B (NF‐ κ B) and Sirt1 to decrease the levels of inflammatory markers, like interleukin‐1 β (IL‐1 β ), tumor necrosis factor‐ α (TNF‐ α ), and monocyte chemoattractant protein‐1 (MCP‐1) to inhibit inflammation. Resveratrol could upregulate Sirt1, subsequently promote forkhead box protein O1 (Foxo1), and inhibit p53, thereby modulating the levels of apoptotic proteins Bim and Bax and antiapoptotic protein Bcl, which could regulate apoptosis.

– Robust human mechanistic evidence: Limited. Umbrella/meta-analytic data show moderate-certainty signals for reduced inflammatory markers (e.g. CRP, TNF-α) and improved endothelial function in dysmetabolic populations. Notably, the InCHIANTI prospective cohort found no association between dietary resveratrol metabolite levels and inflammatory markers, cardiovascular disease, cancer, or all-cause mortality in older community-dwelling adults.[2][9][1]

– Preclinical only (mechanistic plausibility, not clinical proof): SIRT1/LKB1-mediated mitochondrial biogenesis, lifespan extension in lower organisms, reductions in senescence markers (p16/p21/SA-β-gal) in animal tissues, and Nrf2/NF-κB modulation are largely in-vitro and animal data and should not be presented to patients as human benefits.[8][10][4]



3. Evidence base and grading

Evidence comprises numerous small RCTs (typically n=20–150, 4 weeks–1 year), a Cochrane review in type 2 diabetes, multiple meta-analyses, umbrella reviews, and one major prospective cohort (InCHIANTI). No RCT has been powered for mortality or incident age-related disease. GRADE-style certainty by outcome (informed by two umbrella reviews using formal GRADE):[2][3]

Outcome	Evidence statement	Certainty (GRADE)	Recommendation
All-cause mortality / longevity	No RCT evidence; large prospective cohort shows no association [1]	Very low (indirectness, no hard-outcome RCTs)	Only in research
Systolic/diastolic BP (in T2DM)	Umbrella review: SBP −7.97 mmHg (95% CI −10.63 to −5.31), DBP −3.55 mmHg (−5.18 to −1.93) [2]	High (in T2DM only)	Conditional (dysmetabolic patients)
Total cholesterol (overweight)	MD −0.19 mmol/L (95% CI −0.32 to −0.06) [2]	High (small effect)	Conditional
Waist circumference	MD −0.80 cm (95% CI −1.40 to −0.20) [2]	High (trivial magnitude)	Conditional
HbA1c (short-term, <12 wk)	MD −1.05% (95% CI −2.09 to −0.02) [3]; Cochrane: insufficient [11]	Moderate/Low (imprecise, short-term)	Conditional
Glycaemic control / insulin resistance	Beneficial but trivial magnitude; mostly low certainty [3]	Low–Moderate	Conditional
Endothelial function	Meta-analysis: improved flow-mediated dilation [9]	Moderate	Conditional
Inflammatory markers (CRP/TNF)	Reduced in dysmetabolic groups; inconsistent overall [2], [9]	Moderate	Conditional
Working memory / cognition	Moderate-certainty benefit signal [2]	Moderate	Conditional (research-leaning)
Epigenetic clocks / senescence burden	No robust human outcome data [7], [10]	Very low	Only in research

– Key limitations across the base: high heterogeneity (I² frequently >80–96% for pharmacokinetics and many outcomes), small samples, short duration, varied formulations/doses, poor bioavailability, risk of publication bias, and effect magnitudes often below minimal clinically important differences. Two independent umbrella reviews concluded current evidence does not support routine resveratrol supplementation for cardiometabolic management despite isolated high-certainty surrogate signals.[2][3][12]

– Critical caveat: favourable effects on surrogates (BP, lipids, HbA1c) should not be extrapolated to reduced cardiovascular events or extended lifespan — that linkage is unproven for resveratrol.



4. Patient selection and indications

Who might reasonably be considered (adjunctive, off-label, with informed consent):

– Middle-aged adults with cardiometabolic risk (type 2 diabetes, metabolic syndrome, overweight/central adiposity, hypertension) — the population with the strongest (surrogate-level) signal.[2][3][9]

– Patients already optimised on guideline-directed therapy who seek an adjunct and understand the modest, unproven-for-outcomes nature.

Poor candidates / restrict to research:

– Healthy young or normal-weight individuals seeking “anti-ageing” — no demonstrable benefit and unfavourable benefit/risk.[1][3]

– Athletes seeking longevity: some data suggest resveratrol may blunt exercise-induced training adaptations; caution advised (mechanistic/limited human data).

Exclusion / avoid or specialist input only:

– Pregnancy and breastfeeding (avoid — oestrogenic activity, teratogenicity in zebrafish; no human safety data).[12]

– Hormone-sensitive conditions (breast, uterine, ovarian cancer; endometriosis) — resveratrol is a phyto-oestrogen binding oestrogen receptors.[12]

– Patients on narrow-therapeutic-index CYP3A4/CYP2D6 substrates, or on anticoagulants/antiplatelets (antiplatelet/COX-inhibitory effect).[12][13]

– Significant hepatic or renal impairment (high-dose nephrotoxicity/hepatotoxicity signals).[13][12]

Regulatory/ethical status: Off-label, unlicensed food supplement. Practice should be adjunctive care with documented informed consent, ideally within a registry or trial framework given absence of hard-outcome data.



5. Assessment and baseline work-up

– History/exam: full medication reconciliation (focus CYP3A4/2D6 substrates, anticoagulants/antiplatelets), personal/family history of hormone-sensitive cancers, hepatic/renal disease, pregnancy status; cardiometabolic risk (QRISK3), BP, weight/waist circumference, BMI.

– Baseline bloods: fasting glucose and HbA1c, lipid profile, LFTs, U&E/eGFR, FBC; TFTs if any thyroid history (goitrogenic signal at chronic high dose).[12]

– Optional/expert-consensus biomarkers (for follow-up interest only, not validated to guide therapy): hs-CRP, blood pressure logging, body composition. Epigenetic-age clocks and senescence panels are research tools — do not use to justify treatment or claim benefit.[7][10]

– Risk stratification: low risk = healthy, no interacting drugs; moderate = dysmetabolic, some polypharmacy; high risk = hepatic/renal impairment, hormone-sensitive disease, anticoagulation, pregnancy → avoid or specialist input.

– Document: indication, off-label status, consent, baseline BP/weight/waist, baseline bloods, formulation and dose.



6. Dosing regimens and practical implementation

– Best-supported practical dose: 100–500 mg/day of trans-resveratrol, orally, once daily — the range that balances measurable plasma levels against a very low adverse-event risk; most marketed supplements sit here. Bioavailability is poor and highly variable; plasma C_max rises roughly linearly with dose but absolute levels remain low (mean C_max ~31 ng/mL across doses).[12][14]

– Dose–response: Trials used 8 mg to 1000+ mg/day; higher supplement doses have not shown proportionally greater clinical benefit and increase interaction/toxicity risk. No robust loading/titration data — start and maintain at a fixed low-to-moderate dose.[1][2][11]

– Formulation: trans-resveratrol; taken with food is commonly advised (limited data). Micronised/enhanced-bioavailability formulations exist but lack outcome data.

Dose-dependent plasma concentration data:

Figure 2 The effect of changing the maximum plasma resveratrol concentration ( C max ) observed after administration of individual doses along with the random effects for the created groups.

– Doses requiring caution (extrapolated/early-phase): ≥1 g/day — increasing GI adverse effects and CYP inhibition; ≥2.5–5 g/day associated with nausea/diarrhoea, LFT derangement, and a Phase II oncology signal of renal toxicity. High-dose regimens should not be used in longevity practice.[13][9][12]



7. Monitoring, safety and follow-up

Monitoring plan:

– Clinical: BP, weight/waist, GI tolerance, symptoms of bleeding (if on antiplatelet/anticoagulant), rash.

– Laboratory: LFTs and U&E/eGFR at baseline, ~12 weeks, then annually; HbA1c/lipids at ~3–6 months to assess surrogate response; TFTs if symptomatic or on chronic higher dose.

– Timepoints: review at 6–12 weeks (tolerability, baseline repeat bloods), 6 months (surrogate response, decide continuation), then annually.

Adverse effects:[12][13][9]

– Common (mainly ≥1–2.5 g/day; uncommon at 100–500 mg): GI — nausea, abdominal pain, flatulence, diarrhoea.

– Less common: transient rash/skin irritation, headache, myalgia, mild transaminase or bilirubin elevation.

– Serious but rare (high dose): renal toxicity, hepatotoxicity, electrolyte disturbance (reported at multi-gram doses).

– Action on abnormalities: stop for significant LFT rise (>3× ULN), rising creatinine, or unexplained bleeding; reduce dose or stop for persistent GI intolerance; refer if end-organ dysfunction.

Interactions:[12][13]

– CYP3A4 and CYP2D6 inhibition (dose-dependent, more likely >1 g/day) — caution with statins, calcium-channel blockers, certain immunosuppressants, DOACs, and other narrow-index substrates.

– Antiplatelet/COX inhibition — additive bleeding risk with aspirin, NSAIDs, anticoagulants.

– Additive hypotensive/hypoglycaemic effects with antihypertensives and glucose-lowering agents — monitor.

Special populations: Avoid in pregnancy/breastfeeding.[12] Use only with specialist input in hepatic/renal impairment and hormone-sensitive malignancy. Caution and lower threshold to avoid in frail older adults with polypharmacy.



8. Contraindications and cautions

– Absolute (in this practice): pregnancy and breastfeeding; known hypersensitivity.

– Relative / specialist advice needed: hormone-sensitive cancers or oestrogen-dependent conditions; significant hepatic or renal impairment; concurrent anticoagulation/dual antiplatelet therapy; narrow-therapeutic-index CYP3A4/2D6 substrates; active peri-operative period (stop ~1–2 weeks pre-operatively owing to antiplatelet effect — expert consensus).

– Harm likely to outweigh benefit: high-dose (≥1–2.5 g/day) regimens; use in healthy normal-weight individuals expecting anti-ageing benefit; use as a substitute for guideline-directed cardiometabolic therapy.



9. Practical management scenarios

Scenario A — Middle-aged adult with multiple cardiometabolic risk factors (e.g. T2DM/metabolic syndrome).

– Recommendation: Consider as an adjunct (Conditional) — the population with the strongest surrogate-level evidence.[2][3][9]

– Assessment: confirm optimisation of guideline therapy first; baseline BP, HbA1c, lipids, LFTs, U&E, medication review.

– Consent: explain off-label status, modest surrogate-only benefits, no proven mortality/CVD-event benefit.

– Initiation: trans-resveratrol 100–500 mg/day with food.

– Monitoring: BP/waist and tolerability at 6–12 weeks; HbA1c/lipids/LFTs at ~6 months.

– Stop/escalate: discontinue if no meaningful surrogate change by 6 months, if adverse effects, or LFT/renal derangement. Never allow it to displace statin/antihypertensive/antidiabetic therapy.

Scenario B — Older, frail patient with multimorbidity and polypharmacy.

– Recommendation: Avoid / restrict to research (against routine use). Cohort data show no benefit in older adults, and interaction/toxicity risk is amplified by polypharmacy and reduced organ reserve.[1]

– If patient insistent: only after rigorous interaction check (CYP substrates, anticoagulants), lowest dose, close LFT/renal monitoring, and clear documentation.

Scenario C — Adjunct in a patient under specialist care (e.g. cardiology, oncology, hepatology).

– Recommendation: Restrict / defer to specialist. Contraindicated in hormone-sensitive malignancy; caution with immunosuppressants/anticoagulants via CYP and antiplatelet effects.[13][12]

– Process: liaise with the treating specialist before initiation; avoid entirely if on narrow-index CYP3A4 substrates or active cancer therapy; if agreed, low dose with shared monitoring.



10. Research gaps and future directions

– No hard-outcome RCTs: mortality, incident cardiovascular disease, dementia, or frailty have never been endpoints; the InCHIANTI cohort found no mortality association.[1]

– Bioavailability/formulation: poor and highly variable absorption; optimal formulation and whether higher plasma levels translate to benefit remain unresolved.[12]

– Dose optimisation: no established dose–response for clinical (vs surrogate) benefit; the 100–500 mg range is pragmatic, not outcome-validated.[12][14]

– Population targeting: whether benefit is confined to dysmetabolic phenotypes, and the role of gut-microbiota-dependent metabolites (e.g. piceatannol) in responder variability.[15]

– Ageing biomarkers: effects on validated epigenetic clocks and senescence burden in humans are essentially untested; current senescence data are preclinical.[7][10]

– Exercise interaction: possible blunting of training adaptations needs clarification before use in active/athletic populations.

– Practice position: for longevity/anti-ageing endpoints, resveratrol should ideally be used only within well-designed clinical trials or registries; routine clinical use is justifiable at most as a low-dose adjunct in dysmetabolic patients with fully informed consent.

References

1. Resveratrol Levels and All-Cause Mortality in Older Community-Dwelling Adults. Semba RD, Ferrucci L, Bartali B, et al. JAMA Internal Medicine. 2014;174(7):1077-84. doi:10.1001/jamainternmed.2014.1582.
2. Effects of Resveratrol Supplementation on Multiple Health Outcomes: An Umbrella Review of Systematic Reviews and Meta-Analyses of Randomized Controlled Trials. Sun JN, Yang R, Fang L, et al. Nutrition Journal. 2026;25(1):63. doi:10.1186/s12937-026-01319-5.
3. The Effects of Resveratrol Supplementation in Patients With Type 2 Diabetes, Metabolic Syndrome, and Nonalcoholic Fatty Liver Disease: An Umbrella Review of Meta-Analyses of Randomized Controlled Trials. Zeraattalab-Motlagh S, Jayedi A, Shab-Bidar S. The American Journal of Clinical Nutrition. 2021;114(5):1675-1685. doi:10.1093/ajcn/nqab250.
4. Resveratrol-Induced Sirt1 Phosphorylation by LKB1 Mediates Mitochondrial Metabolism. Huang Y, Lu J, Zhan L, et al. The Journal of Biological Chemistry. 2021;297(2):100929. doi:10.1016/j.jbc.2021.100929.
5. Pharmacological Approaches to Decelerate Aging: A Promising Path. Hassani B, Goshtasbi G, Nooraddini S, Firouzabadi N. Oxidative Medicine and Cellular Longevity. 2022;2022:4201533. doi:10.1155/2022/4201533.
6. Sirtuins, Resveratrol and the Intertwining Cellular Pathways Connecting Them. Ungurianu A, Zanfirescu A, Margină D. Ageing Research Reviews. 2023;88:101936. doi:10.1016/j.arr.2023.101936.
7. Therapeutic effects of resveratrol on epigenetic mechanisms in age‐related diseases: A comprehensive review. Zhang S, Kiarasi F. Phytotherapy Research : PTR. 2024;38(5):2347-2360. doi:10.1002/ptr.8176.
8. Effects and Mechanisms of Resveratrol on Aging and Age‐Related Diseases. Zhou DD, Luo M, Huang SY, et al. Oxidative Medicine and Cellular Longevity. 2021;2021:9932218. doi:10.1155/2021/9932218.
9. Resveratrol supplementation efficiently improves endothelial health: A systematic review and meta‐analysis of randomized controlled trials. Mohammadipoor N, Shafiee F, Rostami A, et al. Phytotherapy Research : PTR. 2022;36(9):3529-3539. doi:10.1002/ptr.7562.
10. Therapeutic Effect of Dietary Ingredients on Cellular Senescence in Animals and Humans: A Systematic Review. Guan L, Eisenmenger A, Crasta KC, Sandalova E, Maier AB. Ageing Research Reviews. 2024;95:102238. doi:10.1016/j.arr.2024.102238.
11. Resveratrol for Adults With Type 2 Diabetes Mellitus. Jeyaraman MM, Al-Yousif NSH, Singh Mann A, et al. The Cochrane Database of Systematic Reviews. 2020;1:CD011919. doi:10.1002/14651858.CD011919.pub2.
12. Resveratrol Bioavailability After Oral Administration: A Meta‐Analysis of Clinical Trial Data. Szymkowiak I, Marcinkowska J, Kucinska M, Regulski M, Murias M. Phytotherapy Research : PTR. 2025;39(1):453-464. doi:10.1002/ptr.8379.
13. A mechanistic insight into the anticancer potentials of resveratrol: Current perspectives. Bhuia MS, Chowdhury R, Akter MA, et al. Phytotherapy Research : PTR. 2024;38(8):3877-3898. doi:10.1002/ptr.8239.
14. Climbing the longevity pyramid: overview of evidence-driven healthcare prevention strategies for human longevity. Martinović A, Mantovani M, Trpchevska N, et al. Frontiers in Aging. 2024;5:1495029. doi:10.3389/fragi.2024.1495029.
15. Resveratrol and Vascular Health: Evidence From Clinical Studies and Mechanisms of Actions Related to Its Metabolites Produced by Gut Microbiota. Godos J, Romano GL, Gozzo L, et al. Frontiers in Pharmacology. 2024;15:1368949. doi:10.3389/fphar.2024.1368949.